Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.3916
USD
|
-0.23%
|
|
+5.04%
|
-13.93%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
122.1
|
66.28
|
45.65
|
12.6
|
1.823
|
2.353
|
-
|
-
|
Enterprise Value (EV)
1 |
122.1
|
66.28
|
45.65
|
12.6
|
1.823
|
2.353
|
2.353
|
2.353
|
P/E ratio
|
-5.96
x
|
-2.3
x
|
-1.38
x
|
-0.7
x
|
-0.18
x
|
-0.3
x
|
-0.38
x
|
-0.39
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-6,071,472
x
|
-2,358,314
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-8,167,589
x
|
-2,517,201
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,408
|
1,421
|
1,672
|
1,680
|
4,007
|
6,010
|
-
|
-
|
Reference price
2 |
86.70
|
46.65
|
27.30
|
7.500
|
0.4550
|
0.3916
|
0.3916
|
0.3916
|
Announcement Date
|
3/12/20
|
3/18/21
|
5/2/22
|
3/29/23
|
4/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-20.11
|
-28.1
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-22.38
|
-30.21
|
-32.88
|
-17.65
|
-7.492
|
-10.63
|
-13.97
|
-16.88
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-20.46
|
-28.77
|
-32.47
|
-17.87
|
-6.912
|
-10.63
|
-13.97
|
-16.88
|
Net income
1 |
-20.46
|
-28.77
|
-32.47
|
-17.87
|
-6.912
|
-10.63
|
-13.97
|
-16.88
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-14.55
|
-20.25
|
-19.80
|
-10.65
|
-2.500
|
-1.290
|
-1.030
|
-1.010
|
Free Cash Flow
|
-14.95
|
-26.33
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/18/21
|
5/2/22
|
3/29/23
|
4/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-7.834
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.845
|
-7.492
|
-6.092
|
-3.73
|
-5.38
|
-2.449
|
-2.002
|
-1.871
|
-1.468
|
-2.151
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.714
|
-7.452
|
-6.143
|
-3.374
|
-5.35
|
-2.639
|
-1.83
|
-1.593
|
-1.473
|
-2.016
|
Net income
1 |
-7.714
|
-7.452
|
-6.143
|
-3.374
|
-5.35
|
-2.639
|
-1.83
|
-1.593
|
-1.473
|
-2.016
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-4.650
|
-4.500
|
-3.600
|
-2.250
|
-3.150
|
-1.500
|
-1.090
|
-0.9500
|
-0.2400
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
5/2/22
|
5/17/22
|
8/4/22
|
11/16/22
|
3/29/23
|
6/1/23
|
8/9/23
|
11/22/23
|
4/4/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-14.9
|
-26.3
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.01
|
0.04
|
-
|
0
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/18/21
|
5/2/22
|
3/29/23
|
4/4/24
|
-
|
-
|
-
|
Last Close Price
0.3916
USD Average target price
1
USD Spread / Average Target +155.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.93% | 2.35M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|